Celltrion Views Brazilian Approval As Gateway Into Latin America

 
• By Aidan Fry

Celltrion and its local marketing partner Biomm are working to bring biosimilar trastuzumab to the Brazilian market after receiving approval from local medicines agency Anvisa. A rituximab authorization could soon follow.  

RioDeJaneiro
Celltrion is looking to use its approval for biosimilar trastuzumab in Brazil as a base from whicht to expand in Central and South America • Source: Shutterstock

More from Biosimilars

More from Products